Nectar Lifesciences Valuation

Q: What is the Fair Price of NECLF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

NECLF ($0.4) is trading below our estimate of [[fair value]] ($1.14)

Is NECLF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NECLF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NECLF ($0.4) is trading below our estimate of fair value ($1.14)

Significantly Below Fair Value: NECLF is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NECLF?

Key metric: As NECLF is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NECLF. This is calculated by dividing NECLF's market cap by their current earnings.
What is NECLF's PE Ratio?
PE Ratio	68.9x
Earnings	₹107.27m
Market Cap	₹7.39b

NECLF key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	7.7x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does NECLF's PE Ratio compare to its peers?

The above table shows the PE ratio for NECLF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	14.6x
DMC Domesco Medical Import - Export	14.8x	n/a	₫2.2t
524212 Wanbury	13.8x	n/a	₹7.3b
524075 Albert David	10.6x	n/a	₹7.3b
RX BioSyent	19.1x	n/a	CA$135.7m
NECLF Nectar Lifesciences	68.9x	n/a	US$7.4b

Price-To-Earnings vs Peers: NECLF is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the peer average (14.4x).

Price to Earnings Ratio vs Industry

How does NECLF's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NECLF is expensive based on its Price-To-Earnings Ratio (68.9x) compared to the European Pharmaceuticals industry average (20.3x).

Price to Earnings Ratio vs Fair Ratio

What is NECLF's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NECLF PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	68.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NECLF's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.